Upstream Bio (UPB) EBITDA Margin (2023 - 2026)
Upstream Bio's (UPB) quarterly EBITDA Margin came in at 4218.09% in Q1 2026, up 143792.0% year-on-year from N/an in Q1 2025, and up 38.97% quarter-over-quarter from 6911.23% in Q4 2025.
Upstream Bio (UPB) EBITDA Margin (2023 - 2026) Analysis & Trends
Upstream Bio's EBITDA Margin history runs 4 years deep, the most recent figure standing at 4218.09% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 143792.0% year-over-year to 4218.09% in Q1 2026; TTM through Mar 2026 was 5176.49%, a 104914.0% decrease from a year earlier, with the FY2025 full-year figure at 5618.82%, down 233763.0% from the prior year.
- EBITDA Margin advanced to 4218.09% in Q1 2026 per UPB's latest filing, from 6911.23% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1511.43% in Q3 2023 and bottomed at 6911.23% in Q4 2025.
- The 4-year median for EBITDA Margin is 4218.09% (2026), against an average of 4085.84%.
- Across the five-year window, EBITDA Margin plunged 331023 bps in 2025 and surged 143792 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 3184.44% in 2023, then sank by 35 bps to 4293.31% in 2024, then sank by 61 bps to 6911.23% in 2025, then soared by 39 bps to 4218.09% in 2026.
- Per Business Quant, the three latest UPB EBITDA Margin figures stand at 4218.09% (Q1 2026), 6911.23% (Q4 2025), and 5539.39% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Upstream Bio | 347.73 Mn | 347.73 Mn | -3.94 Mn | -4,218.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,218.09% |
| Dec 31, 2025 | -6,911.23% |
| Sep 30, 2025 | -5,539.39% |
| Jun 30, 2025 | -4,732.87% |
| Mar 31, 2025 | -5,656.01% |
| Dec 31, 2024 | -4,293.31% |
| Sep 30, 2024 | -3,112.52% |
| Jun 30, 2024 | -3,439.22% |
| Mar 31, 2024 | -2,345.78% |
| Dec 31, 2023 | -3,184.44% |
| Sep 30, 2023 | -1,511.43% |